ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,919.87
-0.30%
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.00%
US Dollar vs Yen
156.5695
0.20%
Brent Oil
81.94
-0.61%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Marker Therapeutics Inc (MRKR)

  7. Marker Therapeutics Inc (MRKR) ニュース

MRKR

Marker Therapeutics (MRKR)

Marker Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MRKR
日付受信時刻ニュースソース見出しコード企業名
2024/05/1807 : 25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MRKRMarker Therapeutics Inc
2024/05/1605 : 40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2024/05/1605 : 03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
2024/04/0820 : 00GlobeNewswire Inc.Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies NASDAQ:MRKRMarker Therapeutics Inc
2024/03/2606 : 45GlobeNewswire Inc.Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
2024/03/2301 : 30GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:MRKRMarker Therapeutics Inc
2024/03/0122 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2024/02/2621 : 58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2024/01/2221 : 30GlobeNewswire Inc.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601NASDAQ:MRKRMarker Therapeutics Inc
2024/01/0822 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2024/01/0822 : 24GlobeNewswire Inc.Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationNASDAQ:MRKRMarker Therapeutics Inc
2023/12/2201 : 00GlobeNewswire Inc.Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”NASDAQ:MRKRMarker Therapeutics Inc
2023/12/1121 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/12/1121 : 00GlobeNewswire Inc.Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
2023/11/2106 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/11/1007 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/11/1007 : 00GlobeNewswire Inc.Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
2023/11/1006 : 31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
2023/09/1120 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/09/1120 : 00GlobeNewswire Inc.Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
2023/08/3021 : 00GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MRKRMarker Therapeutics Inc
2023/08/1505 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/08/1505 : 30GlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:MRKRMarker Therapeutics Inc
2023/08/1505 : 03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
2023/08/0720 : 22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/08/0720 : 00GlobeNewswire Inc.Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf ProgramNASDAQ:MRKRMarker Therapeutics Inc
2023/07/2620 : 00GlobeNewswire Inc.Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023NASDAQ:MRKRMarker Therapeutics Inc
2023/07/1020 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
2023/07/1020 : 00GlobeNewswire Inc.European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML PatientsNASDAQ:MRKRMarker Therapeutics Inc
2023/07/0605 : 22Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRKRMarker Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRKR

最近閲覧した銘柄

NYSE
KO
Coca Cola
USI
USTECH100
US Tech 100
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
COIN
SOLUSD
Solana
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
FX
USDJPY
US Dollar vs Yen
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有